ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig[1][2][3].
ONO 1301 (ONO-AP 500-02) inhibits collagen-induced aggregation in a concentration-dependent manner, with an IC50 value of 460 nM[3].
ONO-1301 (0-1000 nM) significantly increases alkaline phosphatase (ALP) activity in the primary osteoblasts and ST2 cells[3].
ONO-1301 (6 mg/kg; p.o.; /daily for 4 weeks) improves the hemodynamic status of rats with dilated cardiomyopat after experimental autoimmune myocarditis[1].
| Animal Model: | Eight-week-old male Lewis rats (rat model of myosin-induced experimental autoimmune myocarditis)[1] |
| Dosage: | 6 mg/kg |
| Administration: | Orally; /daily for 4 weeks |
| Result: | Hemodynamic parameters and plasma brain natriuretic peptide (BNP) level were significantly improved. |
[1]. Hirata Y, et al. Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model. Eur J Pharmacol. 2013;699(1-3):81-87.
[2]. Kashiwagi H, et al. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice. J Pharmacol Exp Ther. 2015;353(2):269-278.
[3]. Kanayama S, et al. ONO-1301 Enhances in vitro Osteoblast Differentiation and in vivo Bone Formation Induced by Bone Morphogenetic Protein. Spine (Phila Pa 1976). 2018;43(11):E616-E624.